Dr. Govindan on the Phase I Results of AMG 510 Evaluated in NSCLC

Ramaswamy Govindan, MD
Published: Tuesday, Sep 10, 2019



Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics (PK), and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non–small cell lung cancer. (NSCLC).
 
The study enrolled 38 patients with KRAS G12C mutation and adenocarcinoma, says Govindan. More than 85% of them had more than two prior lines of therapy, making this a typical group of patients with NSCLC. However, the findings thus far have not been typical.
 
AMG 510 was found to be well tolerated and showed antitumor activity. The investigators hope to see similar trends regarding safety, PK, and efficacy when more data becomes available.

<<< 2019 World Conference on Lung Cancer


Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics (PK), and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non–small cell lung cancer. (NSCLC).
 
The study enrolled 38 patients with KRAS G12C mutation and adenocarcinoma, says Govindan. More than 85% of them had more than two prior lines of therapy, making this a typical group of patients with NSCLC. However, the findings thus far have not been typical.
 
AMG 510 was found to be well tolerated and showed antitumor activity. The investigators hope to see similar trends regarding safety, PK, and efficacy when more data becomes available.

<<< 2019 World Conference on Lung Cancer

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication
x